Eli Lilly & Company (NYSE:LLY) ranks among the Best Low Volatility Investments in December 2025. Eli Lilly & Company reached another milestone on November 21, becoming the first drugmaker to join the exclusive $1 trillion club populated by tech behemoths and cementing its position as a weight-loss powerhouse.
The company’s stock has rallied more than 35% this year, owing primarily to the staggering rise of the global weight-loss market.
Moreover, on November 24, Bernstein SocGen Group reiterated its Outperform rating on Eli Lilly & Company , with a $1,300 price target. The firm maintained a favorable view on the drug maker as Eli Lilly & Company continues to investigate potential in the Alzheimer’s disease field using incretin-based medicines.
According to Bernstein SocGen, Eli Lilly & Company would probably devise an alternate clinical trial method than the current trials, possibly addressing earlier-stage Alzheimer’s patients and using a drug like Brenipatide.
Eli Lilly & Company is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world’s largest pharmaceutical companies.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
